Latest Breaking News On - Human immunology biosciences inc - Page 1 : comparemela.com

Asahi Kasei to Buy Swedish Biotech for Rare Disease Drug

Asahi Kasei to Buy Swedish Biotech for Rare Disease Drug
bnnbloomberg.ca - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bnnbloomberg.ca Daily Mail and Mail on Sunday newspapers.

Asahi kaseiNatsuko katsukiVan lanschot kempenHealth partnersMariana oncology incHuman immunology biosciences incAsahi kasei corpBiogen incCalliditas therapeuticsHuman immunology biosciencesGoldman sachs japanBuy calliditas therapeutics

HI-Bio Announces Positive Results From Phase 2 Study Of Felzartamab For Late Antibody-Mediated Rejection In Kidney Transplant Recipients

82% (n=9/11) of patients on felzartamab experienced resolution of antibody-mediated rejection per Banff criteria on biopsy at 24 weeks versus 20% (n

United statesHong kongGeorg boUptal patelKatharina mayerUnited network for organ sharingHuman immunology biosciences incUniversity of viennaDivision of nephrologyEuropean renal associationUniversity viennaNew england journalImmunology biosciencesBanff classificationUnited networkOrgan sharing

HI-Bio Announces Positive Results from Phase 2 Study of Felzartamab for Late Antibody-Mediated Rejection in Kidney Transplant Recipients

HI-Bio Announces Positive Results from Phase 2 Study of Felzartamab for Late Antibody-Mediated Rejection in Kidney Transplant Recipients
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United statesHong kongCaroline fryMorgan warnersUptal patelKatharina mayerHuman immunology biosciences incUnited network for organ sharingUniversity of viennaUniversity viennaDivision of nephrologyEuropean renal associationNew england journalImmunology biosciencesBanff classificationAssociate professor

HI-Bio Presents Positive Interim Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at 61st European Renal Association (ERA) Congress

HI-Bio Presents Positive Interim Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at 61st European Renal Association (ERA) Congress
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United statesHong kongUptal patelMorgan warnersCaroline fryClinical researchEuropean renal associationAachen universityHuman immunology biosciences incImmunology biosciencesStudy investigatorChief medical officerMonograph capitalAlpha wave globalArkin bio capitalJeito capital

Rare disease deal: Biogen buys Hibio for $1 15B up front

In a deal worth up to $1.8 billion, Biogen Inc. is buying Human Immunology Biosciences Inc. (Hibio), bolstering its late-stage immune-disease treatment portfolio and diversifying its pipeline. The massive amount comprises $1.15 billion up front and as much as $650 in potential milestone payments.

Biogen incHuman immunology biosciences incHuman immunology biosciences